High potency manufacturing is an expanding field with a unique set of challenges. Safety remains a primary concern for those handling cytotoxic drug products, as well as the clinicians and patients down the line. Beyond safety, pharmaceutical companies need to plan ahead for how they will manufacture high potency drugs at scale, distributing the end-products worldwide with secure supply chains in place.
AbbVie Contract Manufacturing’s people, processes and facilities encompass the highest Environmental Health and Safety (EHS) industry practices for handling cytotoxic drug compounds. With a clear understanding of your compounds occupational exposure band classification and proven expertise, AbbVie can help you achieve the most efficient and sustainable cytotoxic drug manufacturing workflow.
To minimize risk at every phase, AbbVie Contract Manufacturing first works to comprehensively characterize your compound, determining its occupational exposure band (OEB) hazard rating and implementing any necessary safety steps. With this knowledge, we can help you develop optimal high potency manufacturing processes, clinical trial designs and drug delivery methods. Through core facilities, such as our Sligo, Ireland site, we offer contract manufacturing for cytotoxic drug products with potency classification as low as OEB 5 (<1 μg/m3).
Our people, protocol and facilities operate at the forefront of this new wave of pharmaceutical development, uniting all necessary components to manufacture challenging cytotoxic drug formulas. Our high potency manufacturing capabilities include: